OTLK Stock Forecast & Price Target

Outlook Therapeutics is expected to capitalize on the potential of its proprietary ophthalmic bevacizumab product, LYTENAVA, for the treatment of wet AMD. With preparations for a US commercial launch underway, the company is expanding its payer engagement and building a focused commercial organization with a potential to exceed $500 million in annual US sales by 2030. The company has reported significant sales growth in its Q3 FY26, and with additional promising financial data such as winning its FDA appeal and resubmitting its BLA, Outlook Therapeutics offers great upside potential for investors.

Outlook Therapeutics is facing significant upside potential as it begins U.S. commercialization of its FDA-approved drug LYTENAVA, which has shown promise in treating wet AMD in Europe. However, the company has faced setbacks, including a second CRL issued by the FDA in 2025, causing delays in their ONS-5010 BLA approval process. Additionally, while the European launch of LYTENAVA has been successful, the full commercialization of the drug in other countries is not expected until later in 2026 and 2027, which may impact the company's financial metrics in the short term.